Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 3,682 | $54.01 | $198,864.82 |
DisclosureSEC source: 0000059478-14-000061 · wf-form4_139152758135653.xml · nonDerivative · entry 2 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,649 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Exercise / conversionCommon Stock | 7,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000061 · wf-form4_139152758135653.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 21,552 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000062 · wf-form4_139152760533600.xml · derivative · entry 4 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,552 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Tax withholdingCommon Stock | 10,123 | $54.01 | $546,743.23 |
DisclosureSEC source: 0000059478-14-000062 · wf-form4_139152760533600.xml · nonDerivative · entry 2 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,058 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionCommon Stock | 21,552 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000062 · wf-form4_139152760533600.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Rice Derica WEVP-Global Services and CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 29,781 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000063 · wf-form4_139152762583104.xml · derivative · entry 6 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,781 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Rice Derica WEVP-Global Services and CFO
|
Tax withholdingCommon Stock | 13,804 | $54.01 | $745,554.04 |
DisclosureSEC source: 0000059478-14-000063 · wf-form4_139152762583104.xml · nonDerivative · entry 2 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,552 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Rice Derica WEVP-Global Services and CFO
|
Exercise / conversionCommon Stock | 29,781 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000063 · wf-form4_139152762583104.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000064 · wf-form4_139152764895459.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,405 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 4,418 | $54.01 | $238,616.18 |
DisclosureSEC source: 0000059478-14-000064 · wf-form4_139152764895459.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,150 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000064 · wf-form4_139152764895459.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000065 · wf-form4_139152766608504.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,405 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Tax withholdingCommon Stock | 4,360 | $54.01 | $235,483.60 |
DisclosureSEC source: 0000059478-14-000065 · wf-form4_139152766608504.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,408 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:27 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionCommon Stock | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000065 · wf-form4_139152766608504.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 20:48 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 58,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000074 · wf-form4_139154691289377.xml · derivative · entry 9 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,778 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 20:48 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 27,609 | $54.01 | $1,491,162.09 |
DisclosureSEC source: 0000059478-14-000074 · wf-form4_139154691289377.xml · nonDerivative · entry 2 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,144 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 20:48 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 58,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000074 · wf-form4_139154691289377.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 15:28 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 154 | $55.59 | $8,560.86 |
DisclosureSEC source: 0000059478-14-000067 · wf-form4_139152769822261.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,172 Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 15:28 UTC |
TAI JACKSON PDirector
|
PurchaseCommon Stock | 12,431 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-14-000066 · wf-form4_139152768457586.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,020 F1 · price: This transaction was executed in multiple trades at prices ranging from $53.25 to $53.30. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:28 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GrantRestricted Stock Unit · Derivative | 52,462 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000025 · wf-form4_139113172881101.xml · derivative · entry 8 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,462 Underlying: Common Stock · 52,462 shares Expires 2015-02-01 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:28 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GrantCommon Stock | 113,712 | $54.23 | $6,166,601.76 |
DisclosureSEC source: 0000059478-14-000025 · wf-form4_139113172881101.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,762 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantRestricted Stock Unit · Derivative | 26,581 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000026 · wf-form4_139113174522140.xml · derivative · entry 5 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,581 Underlying: Common Stock · 26,581 shares Expires 2015-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantCommon Stock | 59,575 | $54.23 | $3,230,752.25 |
DisclosureSEC source: 0000059478-14-000026 · wf-form4_139113174522140.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,575 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 20,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000027 · wf-form4_139113175999893.xml · derivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,985 Underlying: Common Stock · 20,985 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantCommon Stock | 43,376 | $54.23 | $2,352,280.48 |
DisclosureSEC source: 0000059478-14-000027 · wf-form4_139113175999893.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,629 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 13,990 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000028 · wf-form4_139113177496754.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,990 Underlying: Common Stock · 13,990 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:29 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 32,248 | $54.23 | $1,748,809.04 |
DisclosureSEC source: 0000059478-14-000028 · wf-form4_139113177496754.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,425 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 9,605 | $54.23 | $520,879.15 |
DisclosureSEC source: 0000059478-14-000029 · wf-form4_139113179100620.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,812 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 8,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000030 · wf-form4_139113180608829.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,394 Underlying: Common Stock · 8,394 shares Expires 2015-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 20,394 | $54.23 | $1,105,966.62 |
DisclosureSEC source: 0000059478-14-000030 · wf-form4_139113180608829.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,163 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 6,995 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000031 · wf-form4_139113182276564.xml · derivative · entry 3 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,995 Underlying: Common Stock · 6,995 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantCommon Stock | 17,438 | $54.23 | $945,662.74 |
DisclosureSEC source: 0000059478-14-000031 · wf-form4_139113182276564.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,494 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GrantRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000032 · wf-form4_139113183927494.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,591 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GrantCommon Stock | 10,342 | $54.23 | $560,846.66 |
DisclosureSEC source: 0000059478-14-000032 · wf-form4_139113183927494.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,170 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000033 · wf-form4_139113185427982.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,591 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantCommon Stock | 20,613 | $54.23 | $1,117,842.99 |
DisclosureSEC source: 0000059478-14-000033 · wf-form4_139113185427982.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,363 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 1,929 | $54.23 | $104,609.67 |
DisclosureSEC source: 0000059478-14-000034 · wf-form4_139113187900623.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,296 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GrantRestricted Stock Unit · Derivative | 10,493 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000035 · wf-form4_139113189285762.xml · derivative · entry 4 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,493 Underlying: Common Stock · 10,493 shares Expires 2015-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GrantCommon Stock | 22,082 | $54.23 | $1,197,506.86 |
DisclosureSEC source: 0000059478-14-000035 · wf-form4_139113189285762.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,384 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantRestricted Stock Unit · Derivative | 5,246 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000036 · wf-form4_139113190759118.xml · derivative · entry 5 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,246 Underlying: Common Stock · 5,246 shares Expires 2015-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 4,859 | $54.23 | $263,503.57 |
DisclosureSEC source: 0000059478-14-000036 · wf-form4_139113190759118.xml · nonDerivative · entry 3 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 13,628 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:31 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 11,923 | $54.23 | $646,584.29 |
DisclosureSEC source: 0000059478-14-000036 · wf-form4_139113190759118.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,230 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000037 · wf-form4_139113192557105.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,591 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,417 | $54.23 | $76,843.91 |
DisclosureSEC source: 0000059478-14-000037 · wf-form4_139113192557105.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 7,635 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 29,288 | $54.23 | $1,588,288.24 |
DisclosureSEC source: 0000059478-14-000037 · wf-form4_139113192557105.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,318 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantRestricted Stock Unit · Derivative | 9,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000038 · wf-form4_139113194050260.xml · derivative · entry 2 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,094 Underlying: Common Stock · 9,094 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantCommon Stock | 9,309 | $54.23 | $504,827.07 |
DisclosureSEC source: 0000059478-14-000038 · wf-form4_139113194050260.xml · nonDerivative · entry 1 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,487 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 1,373 | $54.23 | $74,457.79 |
DisclosureSEC source: 0000059478-14-000039 · wf-form4_139113195575679.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,797 Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:33 UTC |
Zulueta Alfonso GSVP& Pres., Emerging Markets
|
GrantCommon Stock | 11,333 | $54.23 | $614,588.59 |
DisclosureSEC source: 0000059478-14-000040 · wf-form4_139113197450628.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,163 Read SEC document |
| January 28, 2014 Filed Feb 4, 2014 15:28 UTC Amendment |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GrantCommon Stock | 113,712 | $54.23 | $6,166,601.76 |
DisclosureSEC source: 0000059478-14-000068 · wf-form4a_139152771487556.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,975 F1 · balance_after: This amendment is being filed to correct the total holdings as beneficially owned on 1/30/2014. As of 1/30/2014, the reporting person owned 527,975 shares of issuer stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.